Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio)

Angiosarcoma is a rare and aggressive cancer of the endothelial cells. Propranolol, a non-selective β-blocker, was able to initiate apoptosis in angiosarcoma cell lines and its anti-tumor activity has been described in several case reports. The aim of this trial was to prospectively evaluate the anti-tumor activity of propranolol monotherapy in patients with angiosarcoma before proceeding to stan dard of care treatment.

Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Alaa Embaby, Kimberley M. Heinhuis, Nikki S. IJzerman, Anne Miek Koenen, Stephanie van der Kleij, Ingrid Hofland, Hester van Boven, Joyce Sanders, Winette T.A. van der Graaf, Rick L. Haas, Alwin D.R. Huitema, Winan J. van Houdt, Neeltje Steeghs Tags: Original Research Source Type: research